The Bull Rankings scorecard — our quality-growth score is 81 / 100, built from three pillars each graded 0–100 against sector peers: Quality 89, Growth 82, Value 73. At today's price, our reverse-DCF read says the market is implicitly betting on about 5% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
ResMed’s numbers in the quarter ended 2026-06-30 are the kind that make analysts reach for superlatives, yet the stock sits 22% below its 52-week high. The company prints a 26.9% profit margin and 23.1% return on equity, a pair of figures that anchor our quality-growth score at 81/100, with Quality at 89 and Growth at 82. The weakest pillar, Value, clocks in at 73, but the real question is whether the market is pricing in too much optimism: our model’s reverse DCF reads today’s price as requiring only 5% annual free-cash-flow growth for the next decade, a figure that looks modest against the 9.9% revenue growth reported for the same period.
The bull case is simple. A business that can turn nearly 27 cents of every dollar of sales into profit while compounding revenue at nearly 10% is rare. The Sleep and Breathing Health segment sells cloud-connected devices like ApneaLink Air and NightOwl to sleep clinics, hospitals, and home users, while Residential Care Software monetizes the data layer. That mix of hardware, recurring diagnostics, and software moat is why returns stay high and why competitors can’t replicate the stack overnight.
What the business actually is
ResMed sells sleep recorders and cloud-connected diagnostics to three customer groups: sleep labs, hospitals, and patients at home. In the Sleep and Breathing Health segment, devices like ApneaLink Air measure oximetry, respiratory effort, pulse, nasal flow, and snoring for in-lab titration, while NightOwl is a disposable, cloud-linked recorder that uses peripheral arterial tone, actigraphy, and oximetry to estimate the apnea-hypopnea index at home. The Residential Care Software segment monetizes the data layer through AirView, a platform that lets providers monitor therapy compliance and outcomes remotely. The recurring nature of diagnostics and software keeps revenue from vanishing after the initial sale, and the cloud connectivity locks in data network effects that are hard to dislodge.
Why it can (or can't) keep compounding
The durability case rests on durable high returns. Our model’s signal is clear: the company has maintained outsized returns on capital because the device stack is sticky and the software layer compounds value over time. A 23.1% ROE means the business generates nearly a quarter of its equity in profit each year, and a 26.9% margin shows pricing power that survives reimbursement pressure. The moat isn’t just the hardware; it’s the data network that improves with every patient added to AirView. A rival can copy a recorder, but duplicating the longitudinal dataset that trains algorithms and validates outcomes takes years and regulatory clearance.
The valuation question
The market is asking whether 5% free-cash-flow growth for a decade is enough to justify a 22.1 P/E. The implied growth is low relative to the 9.9% revenue growth posted in the quarter ended 2026-06-30, which suggests the price already embeds caution. The PEG ratio of 1.3 further signals that growth is not being stretched to extremes, yet the stock still trades near the top of its 52-week range. The freshest data points—the 1.6 billion in trailing free cash flow and the 230.65 price—frame the debate: the market has accepted modest expectations rather than chasing the narrative.
The bear case
The skeptic’s argument is that the Sleep and Breathing Health segment is mature and that Residential Care Software can’t offset slowing device growth. The weakest pillar in our model, Value at 73, reflects that multiple compression risk. If revenue growth slips below 8%, the 22.1 P/E starts to look rich, especially when the stock sits just 7% below the average one-year target of 247.2. A concrete signal would be a quarter where revenue growth dips into the high single digits and the margin compresses below 25%.
What would change our mind
Two conditions would flip the thesis. First, if the Sleep and Breathing Health segment reaccelerates to double-digit revenue growth, the durability thesis gains fresh legs and the Value pillar would rise. Second, if the Residential Care Software segment crosses 15% of total revenue, the model would recognize a new growth vector that the market has yet to price. Either shift would validate the 5% free-cash-flow growth assumption baked into today’s price.